Retinal Pigmentary Changes, Vision Damage Caused By Bladder Pain Drug Elmiron: Lawsuit
Elmiron manufacturers failed to warn patients and doctors about the risk of retinal pigmentary changes linked to the bladder pain drug, the lawsuit alleges
Elmiron manufacturers failed to warn patients and doctors about the risk of retinal pigmentary changes linked to the bladder pain drug, the lawsuit alleges
Jury will consider evidence in January 2023, involving claims brought by a woman who experienced eye problems from Elmiron after just two years of use.
After preparing a group of 20 Elmiron lawsuits for trial as bellwether test cases, the Court has identified three claims that will go before juries in January, March and May 2023
Side effects of Elmiron caused vision loss, pigmentary changes and other eye damage that could have been avoided if the drug maker had provided proper warnings and instructions for users and the medical community.
After discovering that her Paragard IUD was imbedded, plaintiff required multiple surgeries to have the broken arms of the birth control device removed.
Judge presiding over the litigation has ordered lawyers to submit information about each Elmiron vision loss claim that may be presented in advance of any settlement negotiations
Permanent distortion and blurred vision are the result of retina damage from Elmiron use to treat bladder pain for 12 years
Lawsuits alleging drug makers failed to warn about link between Elmiron and vision problems will be consolidated before a New Jersey state court judge for pretrial proceedings.
The Elmiron Science Day will allow both parties to present non-adversarial presentations to the Court explaining the science behind claims that Elmiron side effects cause vision loss.
Drug makers avoided clinical testing that may have identified the eye injury risks from Elmiron before the drug was placed on the market.